ArticleJA clinical reports2021
Anesthetic management for a patient with myotonic dystrophy with remimazolam.
Article in JA clinical reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Comparison of postoperative nausea and vomiting between Remimazolam and Propofol in Patients undergoing oral and maxillofacial surgery: a prospective Randomized Controlled Trial.BMC anesthesiology · 2023Trial
- Anesthetic Consideration of Patient With Myotonic Dystrophy Type 1: A Case Report and Review of Literature.Clinical case reports · 2026Article
- Continuous Remimazolam Administration by Gastroenterologists for Endoscopic Sedation.Medicina (Kaunas, Lithuania) · 2026Article
- Remimazolam-remifentanil general anaesthesia without muscle relaxants for percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: A retrospective analysis.Indian journal of anaesthesia · 2025Article
- Remimazolam: a comprehensive review.Anaesthesiology intensive therapy · 2025Review
- Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective.International journal of molecular sciences · 2025Review
- Clinical Experience With Remimazolam in Neuroanesthesiology and Neurocritical Care: An Educational Focused Review.Journal of clinical medicine research · 2025Review
- Anesthetic management in the lateral position in a patient with Parkinson's disease who developed severe long-seated forward flexion with the face buried between the knees: a case report.JA clinical reports · 2025Article
- Clinical Application and Research Progress of Remimazolam for Pediatric Patients.Drug design, development and therapy · 2024Review
- Remimazolam in a Pediatric Patient With a Suspected Family History of Malignant Hyperthermia.Journal of medical cases · 2022Article
- Profile of Remimazolam in Anesthesiology: A Narrative Review of Clinical Research Progress.Drug design, development and therapy · 2022Review
- Anesthetic management with remimazolam for a pediatric patient with Duchenne muscular dystrophy.Medicine · 2021Article
- General anesthesia with remimazolam in a patient with mitochondrial encephalomyopathy: a case report.JA clinical reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with myotonic dystrophy may have increased sensitivity to drugs used for anesthesia. We successfully managed general anesthesia in a patient with myotonic dystrophy using a novel intravenous anesthetic, remimazolam. CASE PRESENTATION: The patient was a 46-year-old man, 169 cm in height, and weighing 60 kg. He was diagnosed with myotonic dystrophy 5 years previously. Phacoemulsification for both eyes was scheduled under general anesthesia. Anesthesia was induced with remimazolam 6 mg/kg/h for 1 min and maintained by continuous infusion at 0.25 mg/kg/h during surgery, a 1/4 dose of the standard infusion rate, as indexed by a bispectral index (BIS). Six minutes after remimazolam discontinuation, the patient opened his eyes on verbal command with sufficient spontaneous respiration. Flumazenil (0.2 mg) was administered to boost the patient's recovery.
conclusionIn addition to the short-acting anesthetic remimazolam, the presence of the antagonist flumazenil enabled complete recovery from anesthesia, without postoperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.